Lower survival was associated with the line of the ICB treatment (log-rank p< 0.001; Figure 5a), the type of ICB used (log-rank p = 0.013; Figure 5b), the histological melanoma subtype (log-rank p = 0.009; Figure 5c), BRAF V600 mutation status (log-rank p = 0.009; Figure 5d) and PD-L1 expression (log-rank p = 0.049; Figure 5e). Here, BRAF is linked to melanoma.